{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:08:57Z","timestamp":1758125337007},"reference-count":59,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2020,6,30]]},"DOI":"10.1167\/tvst.9.7.49","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:16:54Z","timestamp":1593544614000},"page":"49","source":"Crossref","is-referenced-by-count":7,"title":["NEI-Supported Age-Related Macular Degeneration Research: Past, Present, and Future"],"prefix":"10.1167","volume":"9","author":[{"given":"Charles","family":"Wright","sequence":"first","affiliation":[{"name":"Division of Extramural Science Programs, National Eye Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna E.","family":"Mazzucco","sequence":"additional","affiliation":[{"name":"Immediate Office of the Director, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Becker","sequence":"additional","affiliation":[{"name":"Office of the Director, National Eye Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Sieving","sequence":"additional","affiliation":[{"name":"Previous Director, National Eye Institute, Bethesda, MD, USA"},{"name":"Ophthalmology and Vision Science, University of California, Davis, Davis, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santa J.","family":"Tumminia","sequence":"additional","affiliation":[{"name":"Office of the Director, National Eye Institute, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.exer.2006.02.010","article-title":"Pegaptanib for the treatment of age-related macular degeneration","volume":"83","author":"Zhou","year":"2006","journal-title":"Exp Eye Res"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jamaophthalmol.2013.713","article-title":"Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study","volume":"131","author":"Klein","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.ophtha.2014.04.040","article-title":"Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study","volume":"121","author":"Myers","year":"2014","journal-title":"Ophthalmology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ophtha.2016.12.002","article-title":"Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus Meetings","volume":"124","author":"Holz","year":"2017","journal-title":"Ophthalmology"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/path.4266","article-title":"Mechanisms of age-related macular degeneration and therapeutic opportunities","volume":"232","author":"van Lookeren Campagne","year":"2014","journal-title":"J Pathol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","article-title":"Complement factor H in AMD: bridging genetic associations and pathobiology","volume":"62","author":"Toomey","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.preteyeres.2017.11.004","article-title":"Towards the application of precision medicine in age-related macular degeneration","volume":"63","author":"Cascella","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"AMD41","DOI":"10.1167\/iovs.18-24289","article-title":"Perspective on AMD pathobiology: a bioenergetic crisis in the RPE","volume":"59","author":"Fisher","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","article-title":"Current advances in the treatment of neovascular age-related macular degeneration","volume":"14","author":"Villegas","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2014.11.005","article-title":"Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy","volume":"45","author":"Whitmore","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1097\/IAE.0b013e3181f57e30","article-title":"Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives","volume":"30","author":"Zarbin","year":"2010","journal-title":"Retina"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments","volume":"127","author":"Rein","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1001\/jama.2009.729","article-title":"Forecasting age-related macular degeneration through 2050","volume":"301","author":"Klein","year":"2009","journal-title":"JAMA"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1086\/377701","article-title":"Age-related macular degeneration\u2014a genome scan in extended families","volume":"73","author":"Majewski","year":"2003","journal-title":"Am J Hum Genet"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/ng.170","article-title":"Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA","volume":"40","author":"Fritsche","year":"2008","journal-title":"Nat Genet"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"7227","DOI":"10.1073\/pnas.0501536102","article-title":"A common haplotype in the complement regulatory gene factor H (HF1\/CFH) predisposes individuals to age-related macular degeneration","volume":"102","author":"Hageman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1126\/science.1133811","article-title":"A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration","volume":"314","author":"Yang","year":"2006","journal-title":"Science"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41598-018-37673-6","article-title":"Complement factor H regulates retinal development and its absence may establish a footprint for age related macular degeneration","volume":"9","author":"Sivapathasuntharam","year":"2019","journal-title":"Sci Rep"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/431426","article-title":"Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration","volume":"77","author":"Zareparsi","year":"2005","journal-title":"Am J Hum Genet"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/hmg\/ddi353","article-title":"Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk","volume":"14","author":"Rivera","year":"2005","journal-title":"Hum Mol Genet"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat Genet"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1073\/pnas.0408835103","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ejhg.2008.140","article-title":"Variation near complement factor I is associated with risk of advanced AMD","volume":"17","author":"Fagerness","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1073\/pnas.0912702107","article-title":"Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration","volume":"107","author":"Chen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1073\/pnas.0912019107","article-title":"Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)","volume":"107","author":"Neale","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye","volume":"134","author":"Anderson","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/ng.2578","article-title":"Seven new loci associated with age-related macular degeneration","volume":"45","author":"Fritsche","year":"2013","journal-title":"Nat Genet"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together","volume":"15","author":"Fritsche","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0197-2456(99)00031-8","article-title":"The Age-Related Eye Disease Study (AREDS): design implications","volume":"20","author":"Age-Related Eye Disease Study Research G","year":"1999","journal-title":"AREDS report no. 1. Control Clin Trials."},{"key":"bib36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research G","year":"2001","journal-title":"Arch Ophthalmol."},{"key":"bib37","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)","volume":"119","author":"Group","year":"2012","journal-title":"Ophthalmology"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research G","year":"2012","journal-title":"Ophthalmology"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research G","year":"2016","journal-title":"Ophthalmology"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ophtha.2013.10.037","article-title":"Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration","volume":"121","author":"Stein","year":"2014","journal-title":"Ophthalmology"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration","volume":"10","author":"Handa","year":"2019","journal-title":"Nat Commun"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.preteyeres.2016.04.008","article-title":"Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes","volume":"53","author":"Khan","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.preteyeres.2016.04.003","article-title":"Risk factors and biomarkers of age-related macular degeneration","volume":"54","author":"Lambert","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ophtha.2009.07.014","article-title":"Reticular pseudodrusen are subretinal drusenoid deposits","volume":"117","author":"Zweifel","year":"2010","journal-title":"Ophthalmology"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ophtha.2016.02.043","article-title":"Pseudodrusen and incidence of late age-related macular degeneration in fellow eyes in the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Zhou","year":"2016","journal-title":"Ophthalmology"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000001002","article-title":"Visual function measures in early and intermediate age-related macular degeneration","volume":"36","author":"Chandramohan","year":"2016","journal-title":"Retina"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ophtha.2018.12.024","article-title":"Longitudinal study of dark adaptation as a functional outcome measure for age-related macular degeneration","volume":"126","author":"Chen","year":"2019","journal-title":"Ophthalmology"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/ICU.0000000000000262","article-title":"Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network","volume":"27","author":"Baker","year":"2016","journal-title":"Curr Opin Ophthalmol"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.12688\/f1000research","article-title":"Recent advances in the management of dry age-related macular degeneration: A review","volume":"6","author":"Bandello","year":"2017","journal-title":"F1000Res"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-3-319-58290-0","article-title":"Dry age-related macular degeneration pharmacology","volume":"242","author":"Wright","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.preteyeres.2014.11.004","article-title":"Retinal microglia: just bystander or target for therapy?","volume":"45","author":"Karlstetter","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-vision-091517-034425","article-title":"Microglia in the retina: roles in development, maturity, and disease","volume":"4","author":"Silverman","year":"2018","journal-title":"Annu Rev Vis Sci"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1167\/iovs.11-9413","article-title":"Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I\/II clinical study","volume":"53","author":"Cukras","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14712598.2019.1575358","article-title":"Complement inhibition as a therapeutic strategy in retinal disorders","volume":"19","author":"Kassa","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/978-3-319-75402-4","article-title":"Validation of iPS cell-derived RPE tissue in animal models","volume":"1074","author":"Khristov","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"475","key":"bib58","doi-asserted-by":"publisher","first-page":"eaat5580","DOI":"10.1126\/scitranslmed.aat5580","article-title":"Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs","volume":"11","author":"Sharma","year":"2019","journal-title":"Sci Transl Med"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1172\/JCI131187","article-title":"Deep learning predicts function of live retinal pigment epithelium from quantitative microscopy","volume":"130","author":"Schaub","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T19:16:57Z","timestamp":1593544617000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6,3]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.9.7.49","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}